特瑞普利单抗联合化疗治疗初治晚期非小细胞肺癌:多中心随机III期试验(CHOICE-01)
CHOICE-01研究纳入465例无EGFR/ALK突变的初治晚期非小细胞肺癌患者,按2:1随机接受特瑞普利单抗240 mg或安慰剂联合化疗。特瑞普利单抗组中位无进展生存期显著延长(8.4个月vs 5.6个月,HR=0.49),总生存期也显著延长(中位未达到vs 17.1个月,HR=0.69)。≥3级不良事件发生率两组相似,总生存获益主要来自非鳞癌亚组。
要点
- 特瑞普利单抗联合化疗较安慰剂显著延长无进展生存期(8.4个月vs 5.6个月,HR=0.49)和总生存期(中位未达到vs 17.1个月,HR=0.69)。
- ≥3级不良事件发生率两组相似;无论PD-L1表达状态如何,疗效相似。
- 高肿瘤突变负荷患者及局灶黏附-PI3K-Akt信号通路突变患者,在特瑞普利单抗组无进展生存期获益更明显。
核心结论
- 特瑞普利单抗联合化疗显著改善初治晚期非小细胞肺癌患者的无进展生存期和总生存期,安全性可控;亚组分析显示总生存获益主要来自非鳞癌亚组。
研究设计与样本
- 多中心随机III期CHOICE-01研究,纳入465例无EGFR/ALK突变的初治晚期非小细胞肺癌患者,按2:1随机分为特瑞普利单抗240 mg组(n=309)和安慰剂组(n=156),每3周给药一次,联合化疗4-6周期,之后维持治疗每3周一次联合标准治疗;分层因素包括PD-L1表达状态、组织学和吸烟状态;主要终点为研究者按RECIST v1.1评估的无进展生存期。
主要发现
- 特瑞普利单抗组中位无进展生存期8.4个月,对照组5.6个月,HR=0.49(95%CI 0.39-0.61,双侧P<.0001)。
- 特瑞普利单抗组中位总生存期未达到,对照组17.1个月,HR=0.69(95%CI 0.53-0.92,双侧P=.0099)。
- ≥3级不良事件发生率两组相似。
- 394份肿瘤样本全外显子组测序显示,高肿瘤突变负荷患者在特瑞普利单抗组无进展生存期更优(中位13.1个月vs 5.5个月,交互P=.026)。
- 局灶黏附-PI3K-Akt信号通路突变患者在特瑞普利单抗组无进展生存期和总生存期均更优(交互P值≤.001)。
关键数值与推荐
- 主要终点无进展生存期:特瑞普利单抗组中位8.4个月 vs 安慰剂组5.6个月,HR=0.49(95%CI 0.39-0.61,双侧P<.0001)。
- 总生存期期中分析:特瑞普利单抗组中位未达到 vs 安慰剂组17.1个月,HR=0.69(95%CI 0.53-0.92,双侧P=.0099)。
- 高肿瘤突变负荷患者无进展生存期:特瑞普利单抗组中位13.1个月 vs 安慰剂组5.5个月,交互P=.026。
- 局灶黏附-PI3K-Akt信号通路突变患者:特瑞普利单抗组无进展生存期和总生存期更优,交互P值≤.001。
临床怎么用
- 作者结论为特瑞普利单抗联合化疗显著改善初治晚期非小细胞肺癌患者的无进展生存期和总生存期,安全性可控;亚组分析显示总生存获益主要来自非鳞癌亚组。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The CHOICE-01 study investigated the efficacy and safety of toripalimab in combination with chemotherapy as a first-line treatment for advanced non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS: Patients (N = 465) with treatment-naive, advanced NSCLC without EGFR/ALK mutations were randomly assigned 2:1 to receive toripalimab 240 mg (n = 309) or placebo (n = 156) once every 3 weeks in combination with chemotherapy for 4-6 cycles, followed by the maintenance of toripalimab or placebo once every 3 weeks plus standard care. Stratification factors included programmed death ligand-1 expression status, histology, and smoking status. The primary end point was progression-free survival (PFS) by investigator per RECIST v1.1. Secondary end points included overall survival and safety. RESULTS: At the final PFS analysis, PFS was significantly longer in the toripalimab arm than in the placebo arm (median PFS, 8.4 v 5.6 months, hazard ratio = 0.49; 95% CI, 0.39 to 0.61; two-sided P < .0001). At the interim OS analysis, the toripalimab arm had a significantly longer OS than the placebo arm (median OS not reached v 17.1 months, hazard ratio = 0.69; 95% CI, 0.53 to 0.92; two-sided P = .0099). The incidence of grade ≥ 3 adverse events was similar between the two arms. Treatment effects were similar regardless of programmed death ligand-1 status. Genomic analysis using whole-exome sequencing from 394 available tumor samples revealed that patients with high tumor mutational burden were associated with significantly better PFS in the toripalimab arm (median PFS 13.1 v 5.5 months, interaction P = .026). Notably, patients with mutations in the focal adhesion-PI3K-Akt signaling pathway achieved significantly better PFS and OS in the toripalimab arm (interaction P values ≤ .001). CONCLUSION: Toripalimab plus chemotherapy significantly improves PFS and OS in patients with treatment-naive advanced NSCLC while having a manageable safety profile. Subgroup analysis showed the OS benefit was mainly driven by the nonsquamous subpopulation.
引用
- Wang Z, Wu L, Li B, et al. Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non-Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01). J Clin Oncol. 2022. PMID: 36206498. doi:10.1200/JCO.22.00727
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。